The TGFBR1*6A (*6A) variant in exon 1 of the TGFBR1 gene has been postulated as a putative tumor susceptibility allele in several studies. We have performed a case-control study in 537 men with histologically verified prostate cancer and in 488 unrelated controls to investigate the association of *6A with prostate cancer. Our results revealed that the frequency of the *6A allele does not differ in men with prostate cancer compared to healthy controls, even in a subset of age-matched cases and controls. There is no compelling evidence for an association of the *6A variant with prostate cancer.
Introduction
Prostate cancer is the most commonly diagnosed visceral malignancy among men in the United States and in the Western world. 1 Although the etiological factors involved in prostate cancer are not yet well understood, there is strong evidence that genetics plays an important role in its initiation and progression. There is evidence that approximately 40% of prostate cancer risk may be explained by heritable factors. 2 Pathways implicated in cell growth, proliferation and differentiation are among the important candidates in understanding the complex molecular mechanisms involved in carcinogenesis. Members of the transforming growth factor beta (TGF-b) superfamily have been shown to be associated with development of several forms of cancer including prostate cancer. Altered expression and mutations in the TGF-b receptors, type I (TGFBR1) and type II (TGFBR2), have been identified in colon, 3 reported a polymorphic variant allele, TGFBR1*6A (*6A), in exon 1 of the TGFBR1 gene, which involves an inframe deletion of three alanines from a nine-alanine stretch in the wild-type allele. Rare variants, TGFBR1*8A (*8A), TGFBR1*10A (*10A), TGFRBR1*11A (*11A) and TGFBR1*12A (*12A), with corresponding numbers of insertions or deletions, have also been reported. Based on the finding of *6A homozygotes only among cancer patients, a higher than expected number of *6A heterozygotes among patients with a diagnosis of cancer than among controls and the fact that *6A mediates TGF-b growth inhibition less effectively than TGFBR1*9A, it was postulated that *6A may act as a tumor susceptibility allele. 11 Following these, several studies have either confirmed or refuted the association of the *6A allele with susceptibility to cancer. 9, 12 Two recent meta-analyses showed that *6A is significantly associated with an increased risk of breast, colon and ovarian cancer 13, 14 but it is not associated with an increased risk of bladder cancer. 13 To date, no study has investigated the association of *6A with prostate cancer. To test the hypothesis that *6A confers an increased susceptibility to prostate cancer, we conducted a case-control study involving 537 cases and 488 controls. Our results show that *6A is not associated with an increased susceptibility to prostate cancer.
Methods

Participants
Participants in this study were 537 men with histologically confirmed prostate cancer from 299 multiplex sibships and 488 unrelated controls. All of the multiplex sibships were ascertained from patients seen at Washington University School of Medicine by staff urologists or were referred by other area urologists, or were participating in prostate cancer support groups or responded to published solicitations.
Control subjects were followed for many years as part of a long-term prostate cancer study in which men were screened at 6 to 12 month intervals with prostate-specific antigen (PSA) blood tests and digitalrectal examination (DRE) of the prostate. 15 The control subjects were required to meet the following four criteria: (a) be at least 65 years old, (b) never have registered a PSA level above 2.5 ng/ml, (c) never have had a DRE suspicious for prostate cancer, and (d) have no known family history of prostate cancer. Family history of prostate cancer was assessed by inquiring about the subjects' brothers, fathers, grandfathers and maternal and paternal uncles. As a result of the first criterion, the control subjects were older than the case subjects. All of the subjects in this study were of European ancestry. The protocol for this study was approved by the Human Studies Committee of Washington University and the Institutional Review Board of the University of Cincinnati. Written informed consent was obtained from all participants.
DNA analysis
The length of the alanine (GCG) repeat was determined by PCR analysis using the primer sequences reported by Pasche et al. 10 The forward primer was labeled with the fluorescent dye FAM. Genomic DNA (20 ng) was amplified in a 10 ml standard PCR reaction mixture with the exception of using AmpliTaq Gold polymerase and 7-deaza-2 0 -deoxy-dGTP substituted for standard dGTP. The amplified fragments were separated by electrophoresis on an ABI 377 automated DNA sequencer. All *6A homozygotes, 50% of *9A homozygotes and *6A/*9A heterozygotes and all samples with rare alleles were retyped for confirmation of allele calling.
Statistical analysis
Maximum likelihood allele frequency estimates for the cases and controls were obtained from the USERM13 subroutine of MENDEL. 16, 17 Allele frequencies in cases and controls were compared using a likelihood ratio test. Let L A , L C and L T denote the respective maximum likelihoods for the cases, controls and the total sample (ie all cases and controls combined). The quantity
is asymptotically distributed as a w 2 with degrees of freedom equal to kÀ1, where k is the maximum number of alleles.
The general design of a case/control study attempts to match cases with controls, either individually or collectively, on all variables thought to be relevant except the variable under study. For genetic studies of the sort reported here, it is critical to draw cases and controls from the same 'breeding population.' For this reason, we have restricted this analysis to men who are of European ancestry. For complex diseases with a variable age-of-onset, however, opinion is divided over the issue of strictly matching for age. Because of their interest in estimating relative-risks, for instance, epidemiologists tend to insist that age always be a matching variable. Many gene-hunting geneticists, however, prefer a form of 'extreme sampling' that calls for choosing the controls to be exceptionally healthy and as far through the 'risk-period' as possible. This design is expected to result in a control sample that is enriched for low-risk alleles, thereby allowing increased power to identify susceptibility loci when compared to the cases. The danger of this extreme sampling design is that we could misidentify an allele as increasing risk for the development of prostate cancer when, in fact, the alternative allele is associated with longevity. To guard against this possibility, we retested the null hypothesis by excluding all cases younger than age 65 years and the oldest controls, thereby creating a post hoc age-matched subgroup of cases and controls. The price paid for this strategy is a reduced sample size for both cases and controls with a concomitant loss of power.
A feature of familial disease-causing susceptibility alleles is that they often give rise to an earlier age-ofonset and/or a more severe disease course. Well-known examples include the BRCA1 and BRCA2 genes for breast cancer and the APP, PSEN1 and PSEN2 loci for Alzheimer's disease. Accordingly, to test the hypothesis that the *6A allele predisposes carriers to a younger ageof-onset for the development of prostate cancer or a more aggressive course of the disease, we carried out paired t-tests in all families segregating the *6A allele. Table 1 reports the genotypic distribution in cases and controls along with the maximum likelihood estimates of the allele frequencies. We observed no rare alleles in the controls and there was no deviation from the expected Hardy-Weinberg proportions (P ¼ 0.37). Three of the 537 case subjects, however, were heterozygous for a rare allele (two were *8A/*9A heterozygotes and one was a *9A/*10A heterozygote). The likelihood ratio test gave no evidence suggesting that the frequency of the TGFBR1 *6A allele differed in men with prostate cancer compared to healthy controls (w 2 ¼ 5.38, df ¼ 3, P ¼ 0.15). Moreover, there is no evidence of a difference in the frequencies of the *6A allele when the subsample of cases is age-matched to the subsample of controls (
Results
Regarding the possible influence of the *6A allele on age-of-onset, we identified 43 families that contained a TGFBR1*6A is not associated with prostate cancer BK Suarez et al mixture of at least one brother who was heterozygous for the *6A allele and at least one brother who was a *9A/*9A homozygote. These families provided 52 paired observations. There was no evidence that genotype influenced age-of-onset (t ¼ 0.52, P ¼ 0.70). Using Gleason score as a surrogate for the aggressiveness of prostate cancer, data were available for two or more affected brothers from 42 segregating families. These sibships provided a total of 51 paired observations. We found no evidence that *6A/*9A heterozygotes had higher Gleason scores than their *9A/*9A affected brothers (t ¼ 0.07, P40.95).
Discussion
The TGFBR1*6A allele came to be considered as a putative tumor susceptibility allele following the observation that homozygosity for this allele was found only in cancer patients. 11 This was further substantiated with a higher than expected proportion of *6A/*9A heterozygotes in the patients compared to the controls. A plausible explanation for these observations could be the fact that *6A provides cells with a growth advantage because it mediates TGF-b growth inhibition less effectively than TGFBR1*9A. 11, 18 Subsequently, several studies have confirmed these initial findings in various tumor types. 9, 13 However, there have also been some unreplicated results, for example, Samowitz et al 12 did not find association of the *6A allele with susceptibility to colon cancer, nor that the *6A homozygotes were confined to cancer patients alone; in bladder cancer as well, Van Tilborg et al 19 did not find significant association with the *6A allele. The results from the latest meta-analysis suggest that several studies were underpowered to determine an association between *6A and cancer.
14 To date, however, no study has been undertaken to associate the *6A variant with prostate cancer. Ours is the first study in this direction. As in other cancer types, TGF-b plays an important role in prostate growth, and its receptors lose expression in prostate cancer cells. 20 Accordingly, variants located in the receptors are natural candidates for altering susceptibility for either the initiation or progression of prostate cancer. However, our study reveals no compelling role for the *6A deletion in prostate cancer. Indeed, although the frequency of the *6A allele is slightly higher in our cases (9.5%) than in our controls (8.5%), we would require a sample size 7.5 times larger for this 1% difference to be significant at Po0.05. Hence, while it is still possible that the *6A allele confers increased susceptibility to prostate cancer, its attributable risk would likely be extremely small. 
